A Phase 1 Study of VX-522 in Participants With Cystic Fibrosis (CF)
Status:
Recruiting
Trial end date:
2024-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the safety and tolerability of VX-522 in
participants 18 years of age and older with cystic fibrosis and a cystic fibrosis
transmembrane conductance regulator (CFTR) genotype not responsive to CFTR modulator therapy.